SUSD3 and neoplasm: Furthermore, an analysis of the GSE120575 dataset, which encompasses 16,291 immune cells from tumor samples of 48 SKCM patients treated with immune checkpoint inhibitors (ICIs), demonstrated that SUSD3 was predominantly expressed in CD4+ Tconv cells, regulatory T (Treg) cells, cytotoxic T lymphocytes, and CD8+ Tex cells within the SKCM microenvironment (Figure 3D).